Compare Stocks: LXEO, ORIC, REPL, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$8.60 -3.0%	$9.17	$6.90 ▼ $12.41	$1.21B	1.33	574,649 shs	384,171 shs
LXEO Lexeo Therapeutics	$3.52 -13.5%	$4.60	$3.45 ▼ $10.99	$333.93M	1.5	855,827 shs	2.42 million shs
ORIC Oric Pharmaceuticals	$13.33 -1.3%	$12.68	$7.23 ▼ $14.93	$1.40B	1	1.22 million shs	1.72 million shs
REPL Replimune Group	$12.96 -3.8%	$12.90	$1.50 ▼ $16.33	$1.26B	0.94	1.86 million shs	1.89 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	-3.04%	-0.46%	-1.04%	-9.66%	+20.79%
LXEO Lexeo Therapeutics	-13.51%	-15.38%	-28.46%	-25.11%	-34.21%
ORIC Oric Pharmaceuticals	-1.26%	+6.30%	-0.97%	+40.91%	+27.19%
REPL Replimune Group	-3.79%	0.00%	-11.90%	+16.44%	+199.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$8.60 -3.0%	$9.17	$6.90 ▼ $12.41	$1.21B	1.33	574,649 shs	384,171 shs
LXEO Lexeo Therapeutics	$3.52 -13.5%	$4.60	$3.45 ▼ $10.99	$333.93M	1.5	855,827 shs	2.42 million shs
ORIC Oric Pharmaceuticals	$13.33 -1.3%	$12.68	$7.23 ▼ $14.93	$1.40B	1	1.22 million shs	1.72 million shs
REPL Replimune Group	$12.96 -3.8%	$12.90	$1.50 ▼ $16.33	$1.26B	0.94	1.86 million shs	1.89 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	-3.04%	-0.46%	-1.04%	-9.66%	+20.79%
LXEO Lexeo Therapeutics	-13.51%	-15.38%	-28.46%	-25.11%	-34.21%
ORIC Oric Pharmaceuticals	-1.26%	+6.30%	-0.97%	+40.91%	+27.19%
REPL Replimune Group	-3.79%	0.00%	-11.90%	+16.44%	+199.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	2.63	Moderate Buy	$20.60	139.53% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.13	414.91% Upside
ORIC Oric Pharmaceuticals	2.80	Moderate Buy	$20.18	51.40% Upside
REPL Replimune Group	2.60	Moderate Buy	$12.00	-7.41% Downside

Current Analyst Ratings Breakdown

Latest LXEO, ORIC, REPL, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	LXEO Lexeo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
9/23/2026	ORIC Oric Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$26.00
9/22/2026	LXEO Lexeo Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
9/18/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$20.00 ➝ $21.00
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/11/2026	REPL Replimune Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
8/7/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$12.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$41.70M	28.19	N/A	N/A	$4.09 per share	2.10
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$2.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-159.32%	-90.84%	11/5/2026 (Estimated)

Latest LXEO, ORIC, REPL, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	7.54	7.54
LXEO Lexeo Therapeutics	N/A	13.89	13.89
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
REPL Replimune Group	1.00	5.23	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
LXEO Lexeo Therapeutics	60.67%
ORIC Oric Pharmaceuticals	95.05%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
IMTX Immatics	3.30%
LXEO Lexeo Therapeutics	2.00%
ORIC Oric Pharmaceuticals	5.70%
REPL Replimune Group	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	704	136.69 million	132.18 million	Optionable
LXEO Lexeo Therapeutics	59	82.05 million	80.41 million	Not Optionable
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable
REPL Replimune Group	465	93.80 million	88.73 million	Optionable

LXEO, ORIC, REPL, and IMTX Headlines

Recent News About These Companies

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

September 23 at 10:07 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

September 22 at 6:00 PM | globenewswire.com

Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors

September 22 at 1:27 PM | globenewswire.com

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

September 22 at 11:19 AM | globenewswire.com

Citing Replimune approval, experts say localized cancer meds could redefine care

September 21 at 9:54 AM | biospace.comB

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses

September 18, 2026 | prnewswire.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 18, 2026 | marketbeat.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 17, 2026 | globenewswire.com

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

September 17, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

September 17, 2026 | prnewswire.com

DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

September 16, 2026 | globenewswire.com

Replimune Group consensus price target increased by 29.5% to $19.55

September 16, 2026 | msn.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

September 16, 2026 | prnewswire.com

Squarepoint Ops LLC Takes Position in Replimune Group, Inc. $REPL

September 16, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

September 15, 2026 | globenewswire.com

Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors

September 15, 2026 | globenewswire.com

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

September 15, 2026 | globenewswire.com

Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript

September 15, 2026 | seekingalpha.com

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune ...

September 14, 2026 | reflector.comR

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

September 14, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, ORIC, REPL, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

$8.60 -0.27 (-3.04%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$8.60 0.00 (-0.06%)

As of 07:26 AM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Lexeo Therapeutics NASDAQ:LXEO

$3.52 -0.55 (-13.51%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.44 -0.08 (-2.19%)

As of 07:57 AM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Oric Pharmaceuticals NASDAQ:ORIC

$13.33 -0.17 (-1.26%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$13.30 -0.03 (-0.23%)

As of 08:13 AM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Replimune Group NASDAQ:REPL

$12.96 -0.51 (-3.79%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.96 +0.00 (+0.04%)

As of 07:54 AM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXEO, ORIC, REPL, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXEO, ORIC, REPL, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXEO, ORIC, REPL, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, ORIC, REPL, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

Lexeo Therapeutics NASDAQ:LXEO

Oric Pharmaceuticals NASDAQ:ORIC

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LXEO, ORIC, REPL, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LXEO, ORIC, REPL, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LXEO, ORIC, REPL, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, ORIC, REPL, and IMTX Company Descriptions

Immatics NASDAQ:IMTX

Lexeo Therapeutics NASDAQ:LXEO

Oric Pharmaceuticals NASDAQ:ORIC

Replimune Group NASDAQ:REPL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools